...
首页> 外文期刊>International Journal of Pharmaceutics >Preparation of amorphous cefuroxime axetil nanoparticles by controlled nanoprecipitation method without surfactants.
【24h】

Preparation of amorphous cefuroxime axetil nanoparticles by controlled nanoprecipitation method without surfactants.

机译:不用表面活性剂的受控纳米沉淀法制备无定形头孢呋辛酯酯纳米颗粒。

获取原文
获取原文并翻译 | 示例
           

摘要

Amorphous nanoparticles of cefuroxime axetil (CFA), a poorly water-soluble drug, were produced by the controlled nanoprecipitation method without any surfactants at room temperature. The influence of the operation parameters, such as the types of solvent and anti-solvent, the stirring speed, the solvent/anti-solvent (S/AS) volume ratio, the drug concentration and the precipitation temperature, were experimentally investigated. The results indicated that increasing the stirring speed and the S/AS volume, decreasing the drug concentration and the temperature favored to decrease the particle size from 700 to 900nm to approximately 300nm. The XRD analyses confirmed that the as-prepared CFA was amorphous nanoparticles. Furthermore, the amorphous CFA nanoparticles exhibited significantly enhanced dissolution property when compared to the commercial spray-dried product. The results demonstrated that the controlled nanoprecipitation method is a direct and feasible technology which could be utilized for preparation of the poorly water-soluble pharmaceutical nanoparticles.
机译:头孢呋辛酯(CFA),一种水溶性差的药物,是通过受控的纳米沉淀法在室温下不用任何表面活性剂制备而成的非晶态纳米颗粒。实验研究了溶剂和反溶剂类型,搅拌速度,溶剂/反溶剂(S / AS)体积比,药物浓度和沉淀温度等操作参数的影响。结果表明,增加搅拌速度和S / AS体积,降低药物浓度和温度有利于将粒径从700nm降低至900nm至约300nm。 XRD分析证实了所制备的CFA是无定形的纳米颗粒。此外,与商业喷雾干燥产品相比,无定形CFA纳米颗粒表现出显着增强的溶解性能。结果表明,可控的纳米沉淀法是一种直接可行的技术,可用于制备水溶性差的药物纳米颗粒。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号